IBDEI1AW ; ; 06-AUG-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,23042,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,23042,1,4,0)
 ;;=4^V17.3
 ;;^UTILITY(U,$J,358.3,23042,1,5,0)
 ;;=5^Family h/o Ischemic Heart Dis
 ;;^UTILITY(U,$J,358.3,23042,2)
 ;;=^295305
 ;;^UTILITY(U,$J,358.3,23043,0)
 ;;=V16.6^^125^1400^17
 ;;^UTILITY(U,$J,358.3,23043,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,23043,1,4,0)
 ;;=4^V16.6
 ;;^UTILITY(U,$J,358.3,23043,1,5,0)
 ;;=5^Family h/o Leukemia
 ;;^UTILITY(U,$J,358.3,23043,2)
 ;;=^295298
 ;;^UTILITY(U,$J,358.3,23044,0)
 ;;=V18.61^^125^1400^19
 ;;^UTILITY(U,$J,358.3,23044,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,23044,1,4,0)
 ;;=4^V18.61
 ;;^UTILITY(U,$J,358.3,23044,1,5,0)
 ;;=5^Family h/o Polycystic Kidney
 ;;^UTILITY(U,$J,358.3,23044,2)
 ;;=^321531
 ;;^UTILITY(U,$J,358.3,23045,0)
 ;;=V17.0^^125^1400^20
 ;;^UTILITY(U,$J,358.3,23045,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,23045,1,4,0)
 ;;=4^V17.0
 ;;^UTILITY(U,$J,358.3,23045,1,5,0)
 ;;=5^Family h/o Psychiatric Condition
 ;;^UTILITY(U,$J,358.3,23045,2)
 ;;=^295302
 ;;^UTILITY(U,$J,358.3,23046,0)
 ;;=V19.4^^125^1400^21
 ;;^UTILITY(U,$J,358.3,23046,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,23046,1,4,0)
 ;;=4^V19.4
 ;;^UTILITY(U,$J,358.3,23046,1,5,0)
 ;;=5^Family h/o Skin Condition
 ;;^UTILITY(U,$J,358.3,23046,2)
 ;;=^295324
 ;;^UTILITY(U,$J,358.3,23047,0)
 ;;=V17.1^^125^1400^22
 ;;^UTILITY(U,$J,358.3,23047,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,23047,1,4,0)
 ;;=4^V17.1
 ;;^UTILITY(U,$J,358.3,23047,1,5,0)
 ;;=5^Family h/o Stroke (CVA)
 ;;^UTILITY(U,$J,358.3,23047,2)
 ;;=^295303
 ;;^UTILITY(U,$J,358.3,23048,0)
 ;;=V16.8^^125^1400^12
 ;;^UTILITY(U,$J,358.3,23048,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,23048,1,4,0)
 ;;=4^V16.8
 ;;^UTILITY(U,$J,358.3,23048,1,5,0)
 ;;=5^Family h/o Cancer,Other Specified
 ;;^UTILITY(U,$J,358.3,23048,2)
 ;;=^295300
 ;;^UTILITY(U,$J,358.3,23049,0)
 ;;=V11.1^^125^1400^24
 ;;^UTILITY(U,$J,358.3,23049,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,23049,1,4,0)
 ;;=4^V11.1
 ;;^UTILITY(U,$J,358.3,23049,1,5,0)
 ;;=5^Hx of Affective Disorder
 ;;^UTILITY(U,$J,358.3,23049,2)
 ;;=^295250
 ;;^UTILITY(U,$J,358.3,23050,0)
 ;;=V15.89^^125^1400^46
 ;;^UTILITY(U,$J,358.3,23050,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,23050,1,4,0)
 ;;=4^V15.89
 ;;^UTILITY(U,$J,358.3,23050,1,5,0)
 ;;=5^Hx of Persian Gulf Region Exposure
 ;;^UTILITY(U,$J,358.3,23050,2)
 ;;=^295291
 ;;^UTILITY(U,$J,358.3,23051,0)
 ;;=V11.3^^125^1400^25
 ;;^UTILITY(U,$J,358.3,23051,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,23051,1,4,0)
 ;;=4^V11.3
 ;;^UTILITY(U,$J,358.3,23051,1,5,0)
 ;;=5^Hx of Alcoholism
 ;;^UTILITY(U,$J,358.3,23051,2)
 ;;=^295252
 ;;^UTILITY(U,$J,358.3,23052,0)
 ;;=V15.07^^125^1400^26
 ;;^UTILITY(U,$J,358.3,23052,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,23052,1,4,0)
 ;;=4^V15.07
 ;;^UTILITY(U,$J,358.3,23052,1,5,0)
 ;;=5^Hx of Allergy to Latex
 ;;^UTILITY(U,$J,358.3,23052,2)
 ;;=^322043
 ;;^UTILITY(U,$J,358.3,23053,0)
 ;;=V13.4^^125^1400^27
 ;;^UTILITY(U,$J,358.3,23053,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,23053,1,4,0)
 ;;=4^V13.4
 ;;^UTILITY(U,$J,358.3,23053,1,5,0)
 ;;=5^Hx of Arthritis
 ;;^UTILITY(U,$J,358.3,23053,2)
 ;;=^295267
 ;;^UTILITY(U,$J,358.3,23054,0)
 ;;=V12.72^^125^1400^31
 ;;^UTILITY(U,$J,358.3,23054,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,23054,1,4,0)
 ;;=4^V12.72
 ;;^UTILITY(U,$J,358.3,23054,1,5,0)
 ;;=5^Hx of Colon Polyps
 ;;^UTILITY(U,$J,358.3,23054,2)
 ;;=^303401
 ;;^UTILITY(U,$J,358.3,23055,0)
 ;;=V12.59^^125^1400^30
 ;;^UTILITY(U,$J,358.3,23055,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,23055,1,4,0)
 ;;=4^V12.59
 ;;
 ;;$END ROU IBDEI1AW
